Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
PPD, Inc. has entered into a definitive agreement to sell its wholly-owned subsidiary Piedmont Research Center, LLC to Charles River Laboratories for $46.0 million in cash.
April 3, 2009
By: Tim Wright
Editor-in-Chief, Contract Pharma
PPD, Inc. has entered into a definitive agreement to sell its wholly-owned subsidiary Piedmont Research Center, LLC to Charles River Laboratories for $46.0 million in cash. Piedmont Research Center provides preclinical research and evaluation of anticancer agents and therapies. “Under Beth Hollister’s leadership, Piedmont Research Center has been a solid contributor to our discovery sciences segment since we acquired this business in 2002,” said Fred Eshelman, chief executive officer of PPD. “Although this unit has grown nicely over the years, Piedmont Research Center is somewhat of a niche operation for PPD, and its in vivo and in vitro services should be a better long-term strategic fit for Charles River’s preclinical research business. Following the completion of this divestiture, we intend to continue to focus on our core service businesses and compound partnering programs to drive future revenue and earnings growth.” James C. Foster, chairman, president and chief executive officer of Charles River said, “As pharmaceutical and biotechnology companies increasingly choose strategic outsourcing as the means to accelerate their drug development efforts, they need to rely on their service partners to provide scientific depth and expertise in therapeutic areas. The addition of PRC’s expertise, particularly in oncology, expands Charles River Discovery and Imaging Services’ portfolio of efficacy testing services to better support our clients’ needs. PRC’s long history as a trusted provider to the biopharmaceutical industry fits extremely well with Charles River’s focus on deep scientific expertise and exceptional client service. We welcome PRC to the Charles River family.” PPD anticipates the divestiture will reduce its projected full year 2009 discovery sciences segment revenue by approximately $19.0 million. The transaction is expected to close during the second quarter. Additionally, PPD has acquired Magen BioSciences, Inc., a biotechnology company focused on dermatologic therapies based in Waltham, MA, for $14.5 million in cash. The acquisition expands PPD’s compound partnering program into dermatology, initially in the indications of psoriasis, atopic dermatitis and acne. The move gains PPD a pipeline of compounds through Magen’s exclusive license to develop and commercialize preclinical compounds discovered by Eli Lilly & Co. for dermatologic therapeutics. The acquisition also provides PPD with R&D capability to screen dermatologic compounds to determine efficacy and safety. “By combining Magen’s unique dermal biology expertise and innovative pipeline of compounds with our extensive development experience, we hope to develop compounds that address unmet needs for major dermatological disorders,” said Fred Eshelman, chief executive officer of PPD. “The market is strong and growing for dermatologic products, which generally present fewer development hurdles than other therapeutics and have a more straightforward path to regulatory approval.” Magen’s Sandra Luikenhuis, Ph.D. joined PPD with the acquisition and will oversee development of these compounds in her role as executive director, dermatology. “We see significant potential for the discovery and development of new treatments in dermatology, where few novel products are currently being developed,” said Dr. Luikenhuis. “Magen’s experience will be valuable in helping PPD evaluate future opportunities in this growing therapeutic area.” For the remainder of 2009, PPD anticipates that Magen’s R&D activities will generate a loss from operations of approximately $15.2 million.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !